Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2024-10-18 Regulatory Filings
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
Steriwave receives UAE Regulatory Approval
Regulatory Filings Classification · 95% confidence The document is a press release distributed via the RNS (Regulatory News Service) platform. It announces that Ondine Biomedical Inc. has received regulatory approval for its Steriwave technology in the UAE. This is a corporate announcement regarding business operations and regulatory milestones, which does not fit into specific categories like financial reports, dividends, or board changes. Therefore, it is classified as a general regulatory filing/announcement.
2024-10-18 English
Ondine Biomedical Reports Robust Growth in H1 2024
Interim / Quarterly Report Classification · 100% confidence The document is an 'Unaudited results for the six months to 30 June 2024' report for Ondine Biomedical Inc. It contains comprehensive financial statements (consolidated interim statements of financial position), management commentary, operational highlights, and financial performance analysis for a period shorter than a full fiscal year. It is not a mere announcement of a report, as it includes the actual financial data and statements. Therefore, it is classified as an Interim / Quarterly Report. H1 2024
2024-09-30 English
Collaboration advances Steriwave for ICU Market
Regulatory Filings Classification · 98% confidence The document is an official regulatory announcement (RNS) from Ondine Biomedical Inc. regarding a new research collaboration and the associated issuance of new common shares as payment for services. While it mentions share issuance, the primary purpose is to announce a strategic partnership and clinical trial, which falls under general regulatory announcements. Since it is a formal RNS filing detailing corporate activity, it is classified as a Regulatory Filing (RNS).
2024-09-25 English
Ondine secures C$5 million financing
Capital/Financing Update Classification · 95% confidence The document is an RNS announcement from Ondine Biomedical Inc. regarding a private placement financing of C$5 million through the issuance of new common shares. This falls under the category of capital raising and financing activities. While it involves the issuance of shares, the primary purpose of the announcement is to communicate the securing of financing/capital, making 'CAP' (Capital/Financing Update) the most accurate classification.
2024-09-24 English
Mölnlycke® and Ondine Join Forces Against HAIs
Regulatory Filings Classification · 95% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a strategic partnership between Ondine Biomedical Inc. and Mölnlycke Health Care regarding the distribution of the Steriwave technology. As this is a corporate announcement regarding business operations and partnerships rather than a formal financial report, audit, or specific regulatory filing category like 10-K or IR, it falls under the 'Regulatory Filings' (RNS) category, which serves as the fallback for general corporate announcements.
2024-09-23 English
Ondine announces Board Changes
Board/Management Information Classification · 100% confidence The document is an official announcement from Ondine Biomedical Inc. regarding changes to its Board of Directors, specifically the reappointment of Margaret Shaw and the resignation of Craig Tooman. This content directly matches the definition for Board/Management Information (MANG).
2024-09-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.